Perceptive Advisors’s ProQR Therapeutics PRQR Stock Holding History

Perceptive Advisors’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-722,523	Closed	-$10M	–	115
2019 Q1	$10M	Hold	722,523	–	–	0.28%	57
2018 Q4	$11.3M	Sell	722,523 -38,477	-5%	-$706K	0.43%	47
2018 Q3	$14.7M	Buy	+761,000	New	+$8.09M	0.39%	48
2015 Q1	–	Sell	-100,000	Closed	-$2.17M	–	167
2014 Q4	$2.17M	Hold	100,000	–	–	0.18%	85
2014 Q3	$1.72M	Buy	+100,000	New	+$1.6M	0.17%	75

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Perceptive Advisors's PRQR Position: Q2 2019 in Review

Perceptive Advisors sold out of ProQR Therapeutics (PRQR) in Q2 2019, closing a stake of 722,523 shares — an estimated $10M sold.

Perceptive Advisors first reported a position in PRQR in Q3 2014 and held it in 5 quarters. The position peaked at $14.7M in Q3 2018. 55 funds tracked by Wall St. Rank hold PRQR as of Q2 2019.

Perceptive Advisors reported no remaining ProQR Therapeutics position as of Q2 2019 after selling out during the quarter.
Perceptive Advisors sold 722,523 ProQR Therapeutics shares in Q2 2019, an estimated $10M.
Perceptive Advisors first reported a position in ProQR Therapeutics in Q3 2014 and held it in 5 quarters.
Perceptive Advisors's ProQR Therapeutics position peaked at $14.7M in Q3 2018.
55 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2019.

Based on Perceptive Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.